Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
F2F22B + DL001Z
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Gene Therapies
- Administration
- Intravitreal
01
Overview
F2F22B + DL001Z (also known as FT-003) is an investigational, adeno-associated virus (AAV)-based gene therapy developed by Frontera Therapeutics for the treatment of neovascular (wet) age-related macular degeneration (wAMD). The product utilizes a dual-vector system, where F2F22B and DL001Z represent two separate AAV vectors required to deliver the genetic payload for a full-length monoclonal antibody. By delivering the gene for a potent anti-vascular endothelial growth factor (VEGF) protein directly to the retina via a single intravitreal injection, FT-003 aims to provide sustained therapeutic levels of the protein, thereby reducing the treatment burden associated with frequent anti-VEGF injections. It is currently being evaluated in Phase 1 clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with wAMD.
- Other names
- FT-003FT003FT 003
02
Targets
Beyond the preview
Go deeper on F2F22B + DL001Z.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on F2F22B + DL001Z.